Global Epidermal Growth Factor (EGF) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Epidermal Growth Factor (EGF) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival.

And we only study epidermal growth factor (EGF) in cosmetics and medical fields, and don't consider epidermal growth factor (EGF) for research.

Market Overview:

The latest research study on the global Epidermal Growth Factor (EGF) market finds that the global Epidermal Growth Factor (EGF) market reached a value of USD 149.47 million in 2022. It’s expected that the market will achieve USD 196.13 million by 2028, exhibiting a CAGR of 4.63% during the forecast period.

Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market Restraints

Although epidermal growth factor has developed well in the cosmetics industry in recent years, some countries and regions have strictly controlled the product based on safety considerations. For example, China pointed out in the Frequently Asked Questions about Cosmetics Supervision and Administration (1):
Human oligopeptide-1 is generally used in the medical field. The clinical indications are external use to treat burns, wounds and surgical wound healing, and accelerate the growth of transplanted epidermis. Due to its large molecular weight, EGF is more difficult to be absorbed under normal skin barrier conditions. Once the skin barrier function is incomplete, it may cause other potential safety issues. Based on the considerations of effectiveness and safety, EGF should not be used as a cosmetic raw material. Additions to the formula or products claiming to contain human oligopeptide-1 or EGF are illegal products. This largely limits the development of this product in the Chinese cosmetics industry.

In addition, in recent years, some biomedical materials industry and related companies have achieved rapid development. However, compared with large and powerful companies, small and medium-sized companies have relatively small scale and financial strength, and their market brand influence is still relatively weak. The research and development of biomedical materials is technically difficult and has a long research and development cycle, which requires high R&D capabilities and financial strength of enterprises. The relatively small size of the company limits R&D innovation and the promotion of market brands, which is not conducive to the formation of stronger competitiveness in the industry. At the same time, it is not conducive to the development of the industry.

Region Overview:

From 2023-2028, Asia Pacific is estimated to witness robust growth prospects.

Company Overview:

Pavay is one of the major players operating in the Epidermal Growth Factor (EGF) market, holding a share of 23.40% in 2021.

Pavay was established in 1999 and is a modern high-tech enterprise specializing in the development and production of genetic engineering drugs. Pavay is recognized as a district-level enterprise technology center by the Economic Commission of the Autonomous Region, and has a group of high- and mid-level technical personnel and management talents who have been engaged in the research and development, production and operation of biotechnology for a long time. Pavay is the only professional manufacturer in China that uses eukaryote-yeast expression system to produce recombinant human epidermal growth factor (rhEGF).

Haohai Biotechnology is a high-tech biomedical company focusing on R&D, production and sales of medical biomaterials. The company strategically focuses on the fast-growing therapeutic areas in the medical biomaterials market, including ophthalmology, plastic surgery and wound care, orthopedics, Anti-adhesion and hemostasis, the current products mainly include intraocular lens series, medical hyaluronic acid/sodium hyaluronate series, medical chitosan series, medical collagen sponge series, and external recombinant human epidermal growth factor series.

Segmentation Overview:

Among different product types, Liquid segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the EGF Cream segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Epidermal Growth Factor (EGF) market covered in Chapter 3:

Pavay
Radiant RG-CELL
Shenzhen Watsin Genetech Ltd
LipoTrue, S.L
BIOEFFECT
Haohai Biological Technology

In Chapter 4 and Chapter 14.2, on the basis of types, the Epidermal Growth Factor (EGF) market from 2018 to 2029 is primarily split into:

Liquid
Powder

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Epidermal Growth Factor (EGF) market from 2018 to 2029 covers:

EGF Cream
EGF Lotion
EGF Mask
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)